Pre- and postoperative care for stage I–III NSCLC: which quality of care indicators are evidence-based?

• Published in: Lung cancer (Amsterdam, Netherlands) Vol. 101; pp. 120 - 128
• Main Authors: Numan, Rachel C., PhD, Berge, Martijn Ten, PhD, Burgers, Jacobus A., MD, Klomp, Houke M., MD, van Sandick, Johanna W., MD, Baas, Paul, MD, Wouters, Michel W., MD
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.11.2016
• Subjects: Biopsy, Fine-Needle - methods; Bronchoscopy - methods; Carcinoma, Non-Small-Cell Lung - diagnostic imaging; Carcinoma, Non-Small-Cell Lung - pathology; Carcinoma, Non-Small-Cell Lung - surgery; Carcinoma, Non-Small-Cell Lung - therapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Endosonography - methods; Evidence-Based Medicine - methods; Hematology, Oncology and Palliative Medicine; Humans; Lung cancer; Lung Neoplasms - diagnostic imaging; Lung Neoplasms - pathology; Lung Neoplasms - surgery; Lung Neoplasms - therapy; Mediastinum - diagnostic imaging; Mediastinum - pathology; Neoplasm Staging; Positron-Emission Tomography - methods; Postoperative Care; Preoperative Care; Prospective Studies; Pulmonary/Respiratory; Quality indicator; Quality of Care; Quality of Health Care; Radiotherapy, Adjuvant; Survival Rate; Tomography, X-Ray Computed - methods; Treatment Outcome; Quality of Care; Quality indicator; Lung Cancer; Lung cancer
• ISSN: 0169-5002; 1872-8332
• DOI: 10.1016/j.lungcan.2016.05.022

Highlights • Evidence-based quality indicators for the management of stage I–III NSCLC were identified. • The use of the PET-CT and invasive endoscopic techniques are process indicators. • The use of cytology in combination with histology during bronchoscopy is a process indicator. • The use of preoperative chemoradiation for clinical stage III NSCLC is a process indicator. • The use of postoperative chemotherapy for stage II/III NSCLC is a process indicator.